论文部分内容阅读
甲状腺相关眼病(TAO)是一种累积眼眶的自身免疫性疾病,它与Graves甲状腺功能亢进的关系最为密切,亦可发生于甲状腺功能减退甚至正常甲状腺功能的人群。合并不同甲状腺疾病时TAO临床特点不尽相同。治疗Graves甲亢是治疗TAO的关键之一,通常抗甲状腺药物和甲状腺手术不影响TAO的自然进程,而131I治疗则会导致TAO的发生和进展,但是通过早期干预影响因素如吸烟行为、治疗后甲状腺功能改善、类固醇激素应用等可以改善TAO的转归。
Thyroid associated ophthalmopathy (TAO) is a cumulative orbital autoimmune disease that is most closely associated with Graves’ hyperthyroidism and may also occur in people with hypothyroidism or even normal thyroid function. TAO clinical characteristics of different thyroid diseases vary. Treatment of Graves Hyperthyroidism is one of the key to the treatment of TAO, usually anti-thyroid drugs and thyroid surgery does not affect the natural process of TAO, and 131I treatment will lead to the occurrence and progression of TAO, but through early intervention factors such as smoking behavior, thyroid Improved function, steroid use, etc. can improve the outcome of TAO.